April 2, 2013

DSN caught up with Greg Bradley — president and CEO of Advantage Consumer Healthcare, a full turnkey solution center for over-the-counter medicines reaching the market — for an overview of the new marketing and sales solution company as it has recently brought to market OraSure Technologies' OraQuick Advance, a take-home HIV test kit that the Food and Drug Administration recently approved for the self-care market, and Westport Pharmaceuticals' Zephrex-D, a pseudoephedrine product with a unique point of differentiation.

March 6, 2017

DSN examines chain pharmacy, including in-depth coverage of the specialty market, in this multi-page report.

February 2, 2017

DSN associate editor David Salazar examines the state of the pharmacy industry, including generics, automation and technology, in this multi-page report.

 

January 4, 2017

DSN associate editor David Salazar examines the state of the pharmacy industry in this multi-page report.

December 7, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of automation and technology, in this multi-page report.

November 14, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of generics, in this multi-page report.

August 3, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy spending, telehealth, generics and technology, in this multi-page report.

June 1, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy technology, in this multi-page report.

April 14, 2016

DSN examines chain pharmacy, including in-depth coverage of specialty pharmacy, orphan drugs and biosimilars, in this multi-page report.

 

December 30, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, specialty pharmacy and top trends, in this multi-page report.

December 9, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, technology, automation, prescription drug home delivery services and Web-based diabetes monitoring, in this multi-page report.

November 11, 2015

DSN examines chain pharmacy, including in-depth coverage of generics, regulations, technology, automation and medication synchronization, in this multi-page report.

October 13, 2015

DSN examines chain pharmacy, including in-depth coverage of retail clinics, technology, automation, medication synchronization and generics, in this multi-page report.

September 28, 2015

Aurobindo’s latest generic is of Pfizer’s Lopid, which treats high cholesterol alongside diet and exercise.

September 28, 2015

Under the terms of the consent decree, the company will not be allowed to manufacture or sell dietary supplement products until the FDA has determined that the business is in compliance.

September 28, 2015

Mylan’s latest generic, recently approved by the Food and Drug Administration, is intended to treat schizophrenia and schizoaffective disorder.

September 25, 2015

The Food and Drug Administration on Friday approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar control in adults with diabetes mellitus. Both Tresiba and Ryzodeg are manufactured by Novo Nordisk.

September 24, 2015

Aurobindo Pharma on Thursday announced that the Food and Drug Administration had approved its generic of AstraZeneca’s Prilosec (omeprazole) delayed-release capsules. 

September 23, 2015

The Food and Drug Administration on Wednesday announced the approval of Taiho Oncology’s Lonsurf (trifluridine and tipiracil).

September 22, 2015

As many as 84% of consumers say they check the expiration date at least sometimes when using an OTC medicine for themselves. 

September 22, 2015

Impax Laboratories announced Tuesday that the Food and Drug Administration had approved its generic of Valeant’s Testred (methyltestosterone) capsules.

September 22, 2015

Perrigo received Food and Drug Administration approval for a therapeutic equivalent to Valeant’s BenzaClin acne treatment. 

September 22, 2015

Keveyis was recently approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. 

September 21, 2015

This is Impax’s first drug to be approved following its Sept. 4 resolution of issues outlined by the FDA in a warning letter to the company.